Table 1 Demographic data about the patients treated for acute cholecystitis during the COVID-19 pandemic comparing those who survived (n = 2482) and those who died (n = 64)
Variable | Alive | Dead | p |
|---|---|---|---|
N = 2482 | N = 64 | ||
Age | 61.84 (17.2) | 74.6 (14.8) | < 0.001 |
Gender | 0.21 | ||
Male | 1294 (52.2%) | 39 (60.9%) | |
Female | 1184 (47.8%) | 25 (39.1%) | |
Setting of acquisition | 0.004 | ||
Community based | 2098 (89.4%) | 44 (75.9%) | |
Hospital based | 248 (10.6%) | 14 (24.1%) | |
Delay in ED visit (from the onset of symptoms to ED admission) | Mean 3.66 (days) SD 7.4 | Mean 5.17 (days) | |
SD 9.1 | |||
COVID-19 infection | 155 (6.2%) | 24 (37.5%) | < 0.001 |
Immunodeficiency | 103 (4.2%) | 7 (10.9%) | 0.02 |
Malignancy | 167 (6.8%) | 9 (14.1%) | 0.04 |
Severe cardiovascular disease | 510 (20.6%) | 33 (51.6%) | < 0.001 |
Diabetes | < 0.001 | ||
No diabetes | 1910 (77%) | 37 (57.8%) | |
Prediabetes | 45 (1.8%) | 2 (3.1%) | |
History of diabetes | 134 (5.4%) | 3 (4.7%) | |
Diabetes without complications | 318 (12.8%) | 14 (21.9%) | |
Diabetes with complication | 74 (3%) | 8 (12.5%) | |
Severe CKD | 90 (3.6%) | 8 (12.5%) | 0.003 |
Severe COPD | 159 (6.4%) | 16 (25%) | < 0.001 |
ARDS | 35 (1.4%) | 16 (25.4%) | < 0.001 |
PIPAS score | 0 (0–1) | 2.5 (1–4) | < 0.001 |
WSES sepsis severity score | 1 (0–3) | 5 (2–8) | < 0.001 |